ZURICH, Sept 30 (Reuters) - Novartis (NOVN.VX) has hit back against legal claims from the Independent Director Committee of Alcon (ACL.N), the U.S. eyecare group it is seeking to buy out, in a sign a legal battle between the two parties is heating up.
